熱門資訊> 正文

Bicara Therapeutics GAAP每股收益为-0.67美元

2025-11-10 21:51

Bicara Therapeutics Inc.(BCAX) 0
Strategy(MSTR) 0

Bicara Therapeutics press release (BCAX): Q3 GAAP EPS of -$0.67.
Cash, Cash Equivalents and Investments: As of September 30, 2025, Bicara had cash, cash equivalents and investments of $407.6 million, compared to $489.7 million in cash and cash equivalents as of December 31, 2024.

More on Bicara Therapeutics

Bicara Therapeutics: Promising, But Only For The Patient
ClearBridge Small Cap Strategy adds KWR, RNA, exits SEAT, GDRX among Q3 moves
Piper Sandler initiates coverage of oncology companies
Seeking Alpha’s Quant Rating on Bicara Therapeutics
Historical earnings data for Bicara Therapeutics

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。